淋巴细胞胞质蛋白2(lymphocyte cytosolic protein 2,LCP2)是一种衔接蛋白质,在T细胞受体信号通路中扮演重要角色,激活下游信号因子以完成机体的免疫应答过程。LCP2也在恶性肿瘤的发生发展与转移中发挥重要作用,其高表达会导致不良的预...淋巴细胞胞质蛋白2(lymphocyte cytosolic protein 2,LCP2)是一种衔接蛋白质,在T细胞受体信号通路中扮演重要角色,激活下游信号因子以完成机体的免疫应答过程。LCP2也在恶性肿瘤的发生发展与转移中发挥重要作用,其高表达会导致不良的预后效果,降低患者生存率,其具体作用机制涉及多条信号通路。本文不仅对LCP2的分子结构以及基本功能进行了介绍,而且重点综合评述了LCP2通过参与NF-κB、MAPK、JAK/STAT以及PD-1/PD-L1信号通路调控恶性肿瘤发生与发展的分子机制。总结了LCP2作为肿瘤治疗靶点的潜在作用,为将来用于相关疾病的诊断、治疗和标志物筛选等提供理论基础和参考依据。展开更多
目的探讨接头相关复合体蛋白3亚基2(adaptor related protein complex 3 subunit mu 2,AP3M2)在胃癌中的表达情况及其临床意义。方法通过TCGA数据库、实时荧光定量PCR及免疫印迹实验检测AP3M2基因的mRNA及蛋白在胃癌组织中的表达情况。...目的探讨接头相关复合体蛋白3亚基2(adaptor related protein complex 3 subunit mu 2,AP3M2)在胃癌中的表达情况及其临床意义。方法通过TCGA数据库、实时荧光定量PCR及免疫印迹实验检测AP3M2基因的mRNA及蛋白在胃癌组织中的表达情况。通过检测KM Plotter网站探索AP3M2的表达与胃癌患者预后的关系。通过平板克隆形成实验检测AP3M2对胃癌细胞的作用。结果TCGA数据库数据及本研究收集的胃癌患者组织显示AP3M2相比于癌旁组织,其在胃癌组织中的mRNA表达水平升高,同时AP3M2的蛋白在胃癌组织中的表达也有上调的现象。同时本研究通过KM Plotter网站分析得到AP3M2的mRNA表达水平与胃癌患者的预后有关,高表达AP3M2的胃癌患者其预后较低表达AP3M2的胃癌患者差。通过在AGS细胞(人胃腺癌细胞)中过表达AP3M2并检测其平板克隆形成能力的变化,发现过表达AP3M2可以增强胃癌细胞的克隆形成能力。结论AP3M2在胃癌中高表达,高表达AP3M2与胃癌患者的不良预后有关,且能增强胃癌细胞的克隆形成能力。展开更多
AIM:To examine the expression of downstream of tyrosine kinase(DOK)1-6 genes in normal and breast cancer tissue and correlated this with several clinicopathological and prognostic factors.METHODS:DOK1-6 m RNA extracti...AIM:To examine the expression of downstream of tyrosine kinase(DOK)1-6 genes in normal and breast cancer tissue and correlated this with several clinicopathological and prognostic factors.METHODS:DOK1-6 m RNA extraction and reverse transcription were performed on fresh frozen breast cancer tissue samples(n = 112) and normal background breast tissue(n = 31). Tissues were collected between 1991 and 1996 at two centres and all patients underwent mastectomy and ipsilateral axillary node dissection. All tissues were randomly numbered and the details were only made known after all analyses were completed. Transcript levels of expression were determined using real-time polymerase chain reaction and analyzed against TNM stage, tumour grade and clinical outcome over a 10-year follow-up period.RESULTS:DOK-2 and DOK-6 expression decreased with increasing TNM stage. DOK-6 expression decreased with increasing Nottingham Prognostic Index(NPI) [NPI-1 vs NPI-3(mean copy number 15.4 vs 0.22, 95%CI:2.7-27.6, P = 0.018) and NPI-2 vs NPI-3(mean copy number 7.6 vs 0.22, 95%CI:0.1-14.6, P = 0.048)]. After a median follow up period of 10 years, higherlevels of DOK-2 expression were found among patients who remained disease-free compared to those who developed local or distant recurrence(mean copy number 3.94 vs 0.0000096, 95%CI:1.0-6.85, P = 0.0091), and distant recurrence(mean copy number 3.94 vs 0.0025, 95%CI:1.0-6.84, P = 0.0092). Patients who remained disease-free had higher levels of DOK-6 expression compared to those who died from breast cancer.CONCLUSION:Decreasing expression levels of DOK-2 and DOK-6 with increased breast tumour progression supports the notion that DOK-2 and DOK-6 behave as tumour suppressors in human breast cancer.展开更多
文摘淋巴细胞胞质蛋白2(lymphocyte cytosolic protein 2,LCP2)是一种衔接蛋白质,在T细胞受体信号通路中扮演重要角色,激活下游信号因子以完成机体的免疫应答过程。LCP2也在恶性肿瘤的发生发展与转移中发挥重要作用,其高表达会导致不良的预后效果,降低患者生存率,其具体作用机制涉及多条信号通路。本文不仅对LCP2的分子结构以及基本功能进行了介绍,而且重点综合评述了LCP2通过参与NF-κB、MAPK、JAK/STAT以及PD-1/PD-L1信号通路调控恶性肿瘤发生与发展的分子机制。总结了LCP2作为肿瘤治疗靶点的潜在作用,为将来用于相关疾病的诊断、治疗和标志物筛选等提供理论基础和参考依据。
文摘目的探讨接头相关复合体蛋白3亚基2(adaptor related protein complex 3 subunit mu 2,AP3M2)在胃癌中的表达情况及其临床意义。方法通过TCGA数据库、实时荧光定量PCR及免疫印迹实验检测AP3M2基因的mRNA及蛋白在胃癌组织中的表达情况。通过检测KM Plotter网站探索AP3M2的表达与胃癌患者预后的关系。通过平板克隆形成实验检测AP3M2对胃癌细胞的作用。结果TCGA数据库数据及本研究收集的胃癌患者组织显示AP3M2相比于癌旁组织,其在胃癌组织中的mRNA表达水平升高,同时AP3M2的蛋白在胃癌组织中的表达也有上调的现象。同时本研究通过KM Plotter网站分析得到AP3M2的mRNA表达水平与胃癌患者的预后有关,高表达AP3M2的胃癌患者其预后较低表达AP3M2的胃癌患者差。通过在AGS细胞(人胃腺癌细胞)中过表达AP3M2并检测其平板克隆形成能力的变化,发现过表达AP3M2可以增强胃癌细胞的克隆形成能力。结论AP3M2在胃癌中高表达,高表达AP3M2与胃癌患者的不良预后有关,且能增强胃癌细胞的克隆形成能力。
文摘AIM:To examine the expression of downstream of tyrosine kinase(DOK)1-6 genes in normal and breast cancer tissue and correlated this with several clinicopathological and prognostic factors.METHODS:DOK1-6 m RNA extraction and reverse transcription were performed on fresh frozen breast cancer tissue samples(n = 112) and normal background breast tissue(n = 31). Tissues were collected between 1991 and 1996 at two centres and all patients underwent mastectomy and ipsilateral axillary node dissection. All tissues were randomly numbered and the details were only made known after all analyses were completed. Transcript levels of expression were determined using real-time polymerase chain reaction and analyzed against TNM stage, tumour grade and clinical outcome over a 10-year follow-up period.RESULTS:DOK-2 and DOK-6 expression decreased with increasing TNM stage. DOK-6 expression decreased with increasing Nottingham Prognostic Index(NPI) [NPI-1 vs NPI-3(mean copy number 15.4 vs 0.22, 95%CI:2.7-27.6, P = 0.018) and NPI-2 vs NPI-3(mean copy number 7.6 vs 0.22, 95%CI:0.1-14.6, P = 0.048)]. After a median follow up period of 10 years, higherlevels of DOK-2 expression were found among patients who remained disease-free compared to those who developed local or distant recurrence(mean copy number 3.94 vs 0.0000096, 95%CI:1.0-6.85, P = 0.0091), and distant recurrence(mean copy number 3.94 vs 0.0025, 95%CI:1.0-6.84, P = 0.0092). Patients who remained disease-free had higher levels of DOK-6 expression compared to those who died from breast cancer.CONCLUSION:Decreasing expression levels of DOK-2 and DOK-6 with increased breast tumour progression supports the notion that DOK-2 and DOK-6 behave as tumour suppressors in human breast cancer.
